A Study of Neurophysiological and Inflammatory Biomarkers of Seizures and Brain Injury in Children


About this study

The purpose of this study is to connect brain inflammation measured by biomarkers, with data from advanced EEG technology, and clinical outcomes to provide new predictive information about seizure activity in children with critical brain injuries and epilepsy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Neonates with moderate to severe hypoxic ischemic encephalopathy admitted to the Mayo Clinic neonatal ICU
  • Children with altered mental status admitted to Mayo Clinic pediatric ICU
  • Children (1 month to 18 years) with an epileptic encephalopathy, refractory epilepsy and multiple daily seizures, admitted to our pediatric epilepsy monitoring unit (PEMU) for seizure frequency classification
  • Children (1 month to 18 years) without epilepsy admitted to our PEMU for spell classification and who do not have seizures  

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Eric Payne, M.D., M.P.H.

Closed for enrollment

Contact information:

Eric Payne M.D., M.P.H.

(507) 266-0774


More information


Publications are currently not available

Mayo Clinic Footer